Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-15

Study Completion Date

2017-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to investigate the effects of duloxetine on improvement of brain cortical activity in patients suffering from major depressive disorder using near infrared spectroscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine

NCT00532480

Major Depression

COMPLETED PHASE4

Switching to Duloxetine in Patients With Depression

NCT00696774

Depressive Disorder, Major

COMPLETED PHASE4

The Effect of Duloxetine on Interoceptive Awareness

NCT00337012

Depressive Disorder

UNKNOWN

A Study of the Neurobiology of Depression

NCT01051466

Major Depressive Disorder Healthy Participants

COMPLETED PHASE4

Study of Desvenlafaxine in Treating Major Depressive Disorder.

NCT04364997

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention

medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.

Group Type OTHER

Duloxetine

Intervention Type DRUG

duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duloxetine

duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HAMD-17 more than 12 points
* Participants could understand this study and sign permit
* Participants could receive NIRS measurements
* Participants could comply with the protocol of the study

Exclusion Criteria

* alcohol or substance abuse within 3 months of the study
* ever participate other clinical study related to duloxetine
* previous poor treatment effects of duloxetine
* concomitant use of MAOi within 14 days
* concomitant use of Linezolid
* with uncontrolled glaucoma

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No